NCT06937996View on ClinicalTrials.gov

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

RecruitingOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

May 31, 2035

Study Completion Date

May 31, 2035

Conditions
Pancreatic Cancer Non-resectable
Interventions
DEVICE

NanoKnife

The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.

Trial Locations (1)

07631

RECRUITING

Englewood Hospital, Englewood

All Listed Sponsors
lead

Englewood Hospital and Medical Center

OTHER